FDA panel backs broader access to BPC-157, opening scrutiny on peptide market

Traders Union
All News
Business & Wealth
FDA backs BPC-157 access

Highlights

An FDA panel voted eight to six to end prohibitions on BPC-157, despite agency staff concerns about insufficient scientific evidence and regulatory clarity.
The panel's reshaping under Health Secretary Robert F Kennedy Jr, including members with industry ties, raises political and conflict-of-interest concerns influencing peptide deregulation.
Wall Street anticipates the U.S. peptide market, already operating via loopholes and imports from China, could become a multibillion-dollar sector if regulations ease.

Panel vote and regulatory dispute

As first reported by Financial Times, the panel votes eight to six at an FDA meeting in Maryland to end prohibitions on BPC-157, also known on social media as the Wolverine peptide, despite agency staff saying the scientific evidence does not support broader access.

BPC-157 is one of seven peptides the panel is considering for deregulation on Thursday and Friday. The FDA says it is not clear what the substance actually is, a basic issue for the agency before any approval decision, and adds that the drug is not part of an approved product in any country and appears on the World Anti-Doping Agency prohibited list.

Initial studies in animals and cells suggest BPC-157 may reduce inflammation in muscles and tendons and may speed fracture healing. The FDA also warns of risks including ulcerative colitis, while supporters at the meeting argue the agency's analysis is incomplete and say the drugs should be produced domestically through pharmacies rather than circulate through an unregulated grey market.

Political and market implications for peptides

The vote comes after the panel is reshaped under Health Secretary Robert F Kennedy Jr to include pharmacists and doctors who could benefit from peptide sales, with at least six members described as having industry ties. Tennessee state senator Bobby Harshbarger, who votes in favor of deregulation, is also identified as the son of Representative Diana Harshbarger, a pharmacist who has advocated peptide use.

Kennedy has promoted peptides and praised their potential, reinforcing expectations that broader access could advance even if the FDA resists. Paul Kim, a partner at Kendall Square Policy Strategies, says the process is political rather than scientific, while Edgar Asebey of Frier Levitt says the nonbinding vote may give Kennedy cover to overrule any FDA rejection.

Investors are closely watching the sector as pharmacies report contact from potential backers ahead of any rule change. Peptides are already available in the U.S. through regulatory loopholes and are typically shipped from China, and Wall Street estimates suggest the market could develop into a multibillion-dollar business.

Our earlier analysis of Hims & Hers Health (HIMS) focused on a sharp intraday rebound that reversed early losses, while highlighting that the stock was still capped below its 20-day moving average and exposed to elevated volatility. We noted mixed momentum signals: buyers showed strength in the rally, but oscillators pointed to potential exhaustion without fresh catalysts, leaving near-term upside dependent on a decisive technical break.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.